Health and Human Services Secretary Tom Price’s questioning of the benefits of medication-assisted treatment for opioid abuse doesn’t signal a change in federal policy, the Trump administration said Friday.

Price raised concerns Tuesday during a West Virginia listening tour about opioid abuse when he questioned the benefits of addiction medications such as buprenorphine and methadone.

Recommended Stories

WATCH LIVE: Trump campaigns in Iowa just days before midterm elections

Teamsters President Sean O’Brien backs Ashley Moody in Florida Senate race

Democrats shred Haley Stevens after defection to Mike Rogers: ‘Despicable betrayal’